By the end of this session, you should be able to: 1. Recognize the major etiologies of chronic liver disease and their distinguishing features 2. Interpret liver function tests (LFTs) and hepatic synthetic markers 3. Use non-invasive fibrosis assessment tools (FIB-4, VCTE, MRE) to stage liver disease 4. Explain the pathophysiology of major complications (portal hypertension, ascites, hepatic encephalopathy) 5. Discuss evidence-based management of chronic liver disease 6. Identify when to refer patients to specialist hepatology care 7. Understand the role of newer medications (e.g., resmetirom for NASH) in modern hepatology
| Marker | Source | Elevation Pattern | Clinical Meaning |
|---|---|---|---|
| ALT (Alanine aminotransferase) | Hepatocyte cytoplasm | Mild-moderate ↑ | Hepatocellular injury (viral, autoimmune, toxin) |
| AST (Aspartate aminotransferase) | Hepatocyte mitochondria + cytoplasm | Variable | Hepatocellular injury; AST:ALT >2 → alcoholic liver disease |
| ALP (Alkaline phosphatase) | Bile duct epithelium | ↑ | Cholestatic or infiltrative disease |
| GGT (Gamma-glutamyl transferase) | Bile duct epithelium | ↑ with ALP | Confirms hepatic origin of ALP elevation |
| Total Bilirubin | Liver metabolism/excretion | ↑ | Impaired clearance or cholestasis |
| Direct Bilirubin | Liver conjugation | ↑ | Intrahepatic or extrahepatic cholestasis |
| Albumin | Synthetic function | ↓ | Advanced cirrhosis; poor prognosis |
| INR/PT | Synthetic function | ↑ (prolonged) | Impaired clotting factor synthesis; cirrhosis |
Hepatocellular Pattern (ALT/AST ↑↑, ALP mild ↑): - Viral hepatitis, autoimmune hepatitis, drug-induced injury, alcoholic hepatitis - ALT usually >AST (except in alcoholic hepatitis where AST:ALT >1.5)
Cholestatic Pattern (ALP/GGT ↑↑, ALT/AST mild ↑): - Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), drug toxicity, pregnancy - ALP ↑ confirmed by GGT
Mixed Pattern (Both ↑↑): - Acute hepatitis, infiltrative disease, cirrhosis
Synthetic Dysfunction (↓ Albumin, ↑ INR): - Indicates advanced disease: Cirrhosis or fulminant hepatic failure - Normal LFTs with low albumin/↑ INR = cirrhosis until proven otherwise
Formerly NAFLD; new name emphasizes metabolic etiology, not absence of alcohol
Epidemiology: - Most common liver disease globally (~30% of adults) - Linked to obesity (BMI ≥25), diabetes, hypertension, dyslipidemia
Pathophysiology: - Hepatic triglyceride accumulation (>5% of liver weight) - Steatohepatitis (MASH) = steatosis + inflammation + fibrosis - Risk: Progression to cirrhosis in 15-20% over 10 years
Diagnosis: - Imaging (ultrasound, CT, MRI) showing steatosis - ≥1 cardiometabolic risk factor - Exclusion of other liver diseases
Risk Stratification: - FIB-4 score = (Age × AST) / (Platelets × √ALT) - FIB-4 <1.3 (or <2.0 if age >65): Low risk - FIB-4 1.3-2.67: Intermediate; needs second-line testing - FIB-4 >2.67: High risk; likely advanced fibrosis - VCTE (FibroScan): <8 kPa = low risk; >12 kPa = high risk - MRE: Most accurate non-invasive method; thresholds 3.0-5.0 kPa by fibrosis stage
Management: - Weight loss: 7-10% for improvement; >10% for regression - Exercise: 150 min moderate-intensity weekly - Diet: Mediterranean or low-carbohydrate patterns - Medications: Resmetirom (recently FDA approved for MASH with F1B-F3 fibrosis)
Resmetirom (Rezdiffra) — New Game-Changer: - Mechanism: Selective thyroid hormone receptor-β (THR-β) agonist - Effect: Enhances fatty acid oxidation; decreases steatosis; improves fibrosis - MAESTRO-NASH trial: 26-30% achieved NASH resolution + fibrosis improvement (vs. 9-14% placebo) - Side effects: Diarrhea (30%), nausea (20%), abdominal pain (15%) — mostly mild, transient - Starting dose: 80 mg daily; can titrate to 100 mg - Indication: F1B-F3 fibrosis (biopsy-confirmed NASH)
Epidemiology: - Second most common cause of cirrhosis (after MASLD) - Requires heavy alcohol use (typically >60 g/day for men, >40 g/day for women, for years) - Risk of cirrhosis: ~10-15% of heavy drinkers
Spectrum: - Fatty liver: Usually reversible with abstinence - Alcoholic hepatitis: Acute inflammation; mortality 30-40% if severe - Cirrhosis: Advanced, often irreversible; high decompensation risk
Key Laboratory Finding: - AST:ALT ratio >2.0 (AST elevated more than ALT, unlike viral hepatitis) - AST typically <300 U/L (higher values suggest ATN or other cause)
Management: - Alcohol cessation: Absolute requirement; brief intervention, counseling, pharmacotherapy - Nutritional support: BCAA supplementation for sarcopenia - Corticosteroids: Considered in severe acute alcoholic hepatitis (MELD >11 or hepatic encephalopathy) - Liver transplantation: Available for carefully selected patients (6 months sobriety usually required)
Formula: FIB-4 = (Age × AST) / (Platelet count × √ALT)
Interpretation (HCV population): - FIB-4 <1.3: Low probability advanced fibrosis; NPV 95% (if negative, unlikely F3-F4) - FIB-4 1.3-2.67: Intermediate; need second-line test (elastography, biomarkers) - FIB-4 >2.67: High probability advanced fibrosis; PPV 65%
Age-Adjusted Thresholds (for age >65): - Use threshold 2.0 (low risk) and 3.25 (high risk) to reduce false positives
Advantages: Free, requires only routine labs, widely validated Limitations: Less accurate in cirrhosis; affected by inflammation, hemolysis
What It Does: - Measures liver stiffness via shear wave propagation - Stiff liver (fibrosis/cirrhosis) = faster wave travel = higher reading
Interpretation (kPa): - <8 kPa: No significant fibrosis (F0-F1) - 8-12 kPa: Intermediate; need additional testing - >12 kPa: Likely advanced fibrosis or cirrhosis
Advantages: - Point-of-care; rapid; operator-dependent but reproducible with experience - Can be repeated serially to track progression
Limitations: - Fails in obesity (BMI >30) — XL probe helps but still limited - Affected by inflammation, congestion, ascites - No direct visualization of anatomy
Advantages: - Most accurate non-invasive method for fibrosis - Not affected by obesity, operator, inflammation as much - Measures stiffness over entire liver
Interpretation (Standardized Cutoffs): - <3.0 kPa: F0 (no fibrosis) - 3.0-3.5 kPa: F1 (mild) - 3.5-4.0 kPa: F2 (significant) - 4.0-5.0 kPa: F3 (advanced) - >5.0 kPa: F4 (cirrhosis)
Limitations: - Expensive; not universally available; requires MRI (contraindications possible) - Longer acquisition time
FIB-4: Discussed above; free NAFLD Fibrosis Score (NFS): Age, BMI, diabetes, AST:ALT ratio, platelets, albumin Enhanced Liver Fibrosis (ELF): Proprietary blood test measuring hyaluronic acid, TIMP-1, PIIINP APRI: AST-to-platelet ratio; simple but lower performance
Combination Algorithms: - Agile 3+: VCTE + clinical parameters for F3 detection - Agile 4: Optimized for cirrhosis (F4) detection - MEFIB: MRE + FIB-4 score for enhanced accuracy
Baveno VII Criteria: Risk stratify to avoid unnecessary endoscopy
Criteria for LOW variceal bleeding risk (no endoscopy needed): - Platelet count >150,000 - VCTE <20 kPa - If both met: Variceal bleeding risk <5%; can avoid screening endoscopy
Criteria for HIGH risk (endoscopy recommended): - Platelet count ≤150,000 OR VCTE ≥20 kPa - Proceed to upper endoscopy for variceal assessment
1. Variceal Bleeding: - First bleed mortality: 15-20% - Prophylaxis: Beta-blockers reduce bleeding risk by ~40% - Acute treatment: Endoscopic variceal ligation (EVL) >90% success
2. Ascites: - Define as fluid accumulation in peritoneal cavity - Grade 1: Ultrasound only - Grade 2: Mild physical examination findings - Grade 3: Clinically apparent; impairs respiratory function - Management: Sodium restriction (<2 g/day) + diuretics (spironolactone, furosemide)
3. Hepatic Encephalopathy: - Neuropsychiatric dysfunction from portal hypertension + liver failure - Grades 1-4 (subtle confusion → deep coma) - Treatment: Lactulose (osmotic laxative), rifaximin (non-absorbed antibiotic)
4. Spontaneous Bacterial Peritonitis (SBP): - Bacterial infection of ascites without source - Diagnosis: >250 PMN/μL in ascitic fluid culture positive - Treatment: Third-generation cephalosporin (ceftriaxone) - Prophylaxis: Norfloxacin in high-risk patients
Refer immediately if: - Cirrhosis diagnosed (any etiology) - Evidence of portal hypertension (ascites, varices, splenomegaly, platelet <100) - Hepatic encephalopathy present - Child-Pugh B or C class cirrhosis - MELD score >15 (likely transplant candidate)
Refer semi-urgently (weeks) if: - Advanced fibrosis (FIB-4 >2.67 or VCTE >12 kPa) without cirrhosis - Significant ALT/AST elevation without clear etiology - Chronic viral hepatitis needing antiviral therapy - Autoimmune hepatitis suspected
Refer electively (routine referral) if: - MASLD with obesity/metabolic risk factors requiring risk stratification - Recent HCV diagnosis (for DAA therapy evaluation) - Compensated cirrhosis for baseline assessment/surveillance planning
AST:ALT ratio is your friend. >2:1 with AST <300 = alcoholic liver disease. Think alcohol use disorder.
FIB-4 is free and powerful. Use it as a first-line tool to identify high-risk patients needing further workup.
Liver biopsy is rarely needed today. Non-invasive tests (FIB-4, VCTE, MRE) are accurate and safe. Biopsy is reserved for diagnostic uncertainty.
MASLD is not benign. It’s the most common liver disease globally and a leading cause of HCC. Risk-stratify appropriately.
Resmetirom changes the game for NASH. First medication approved specifically for MASH with fibrosis; solid efficacy in trials.
Portal hypertension drives complications. Once VCTE >20 kPa or platelets drop, expect varices, ascites, encephalopathy. Screen and prevent.
Early recognition saves lives. Many cirrhotic patients present after variceal bleed or encephalopathy. Earlier referral for endoscopy/imaging could prevent this.
Transplant evaluation is timely intervention. MELD >15 or decompensation = likely transplant candidate. Don’t miss the window.
| Disease | Epidemiology | Key Lab Finding | Diagnosis | Treatment Goal |
|---|---|---|---|---|
| MASLD | 30% population; obesity/DM | ↑ ALP, normal LFTs early | Imaging + risk factors | Weight loss; resmetirom for MASH |
| Alcoholic LD | 2% population; heavy EtOH use | AST:ALT >2, AST <300 | Clinical hx; exclude others | Abstinence; transplant if severe |
| HBV | 296M globally; sexual/vertical | HBsAg+; HBV DNA | Serology; HBV DNA quantitation | NRTI therapy; suppress replication |
| HCV | 58M globally; IVDU/transfusion | Anti-HCV+; HCV RNA | Serology; HCV RNA quantitation | DAA therapy; cure (>95%) |
| AIH | 1:100,000; autoimmune | ↑↑ ALT/AST; ↑ IgG; ANA+ | Serology; biopsy if uncertain | Corticosteroids; remission |
| PBC | 40:100,000; women; autoimmune | ↑↑ ALP/GGT; AMA+ | Serology; imaging | UDCA; obeticholic acid |
| PSC | 15:100,000; associated IBD | ↑↑ ALP/GGT; MRCP | MRCP imaging | Limited; monitor for CCA |
A 55-year-old man with no prior liver disease presents with ALT 280, AST 140, ALP 95, bilirubin 1.2, albumin 3.8, INR 1.0. Ultrasound shows steatosis without cirrhosis.
Most likely diagnosis?
A. Hepatitis C B. Alcoholic liver disease C. Metabolic dysfunction-associated steatotic liver disease (MASLD) D. Primary biliary cholangitis
Answer: C. ALT>AST pattern with mild-moderate elevation, normal synthetic markers, steatosis on imaging, no jaundice = MASLD. In alcoholic liver disease, AST:ALT would be >2. HCV typically causes lower transaminase elevations. PBC would show high ALP. This is straightforward MASLD.
A 62-year-old woman with MASLD (steatosis on imaging, BMI 32, hypertension) has labs: age 62, AST 48, ALT 65, platelet 240.
Calculate her FIB-4 index and interpret risk:
FIB-4 = (62 × 48) / (240 × √65) = 2976 / (240 × 8.06) = 2976 / 1934 = 1.54
Interpretation?
A. Low risk; no further workup needed B. Intermediate risk; needs VCTE or MRE C. High risk; likely cirrhosis D. Very high risk; immediate transplant evaluation
Answer: B. FIB-4 = 1.54 = Intermediate risk (falls between 1.3-2.67). This patient needs second-line testing (VCTE or MRE) to better characterize her fibrosis stage. She’s not high-risk yet, but not low-risk either. Don’t stop at FIB-4; continue workup.
A 50-year-old with compensated cirrhosis (VCTE 18 kPa, platelet 160) is found to have esophageal varices (not bleeding). No ascites or encephalopathy.
Best management:
A. Upper endoscopy with variceal ligation (EVL) B. Observe; no intervention needed C. Start beta-blocker (propranolol or carvedilol) D. Immediate hospitalization; prepare for blood transfusion
Answer: C or A (both are correct depending on context). At minimum, start beta-blocker prophylaxis (reduces first-bleed risk ~40%). EVL is also indicated for documented varices in high-risk patients or as elective prophylaxis. Optimal is both: beta-blocker + EVL. Observation alone is inadequate; this patient needs intervention. No bleeding yet, so hospitalization not needed.
Created for PA/Medical Student Education in Hepatology. Last updated February 2026.